Nusinersen

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1076 publications

Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale.

Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale.

Journal: Archives of rehabilitation research and clinical translation

Published: June 22, 2026

Correction: Clinical outcome and efficacy of nusinersen in Korean adult patients with 5q spinal muscular atrophy: Nationwide multicenter retrospective study.

Correction: Clinical outcome and efficacy of nusinersen in Korean adult patients with 5q spinal muscular atrophy: Nationwide multicenter retrospective study.

Journal: Acta neurologica Belgica

Published: May 28, 2026

Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.

Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.

Journal: Nature reviews. Neurology

Published: May 26, 2026

Nusinersen: the antisense oligonucleotide at the forefront of spinal muscular atrophy treatment.

Nusinersen: the antisense oligonucleotide at the forefront of spinal muscular atrophy treatment.

Journal: RNA biology

Published: May 18, 2026

Lung Function and Respiratory Muscle Strength in Symptomatic Children and Adults With Spinal Muscular Atrophy Treated With Nusinersen.

Lung Function and Respiratory Muscle Strength in Symptomatic Children and Adults With Spinal Muscular Atrophy Treated With Nusinersen.

Journal: Neurology

Published: May 07, 2026

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Journal: Nature medicine

Published: April 23, 2026

Extracellular vesicle-based delivery systems for nucleic acid therapeutics.

Extracellular vesicle-based delivery systems for nucleic acid therapeutics.

Journal: Molecular therapy. Nucleic acids

Published: April 06, 2026

Correction: Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam.

Correction: Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam.

Journal: Journal of neurology

Published: March 28, 2026

Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study.

Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study.

Journal: Neurology and therapy

Published: March 23, 2026

Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI.

Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI.

Journal: Journal of neuromuscular diseases

Published: March 14, 2026

Clinical evaluation of ThecaFlex DRx, a novel implantable catheter-port for intrathecal nusinersen delivery in spinal muscular atrophy: Initial results from the PIERRE-IDE study.

Clinical evaluation of ThecaFlex DRx, a novel implantable catheter-port for intrathecal nusinersen delivery in spinal muscular atrophy: Initial results from the PIERRE-IDE study.

Journal: Journal of neuromuscular diseases

Published: March 14, 2026

Adult SMA REACH: A UK clinical network and real-world data collection study for adults living with spinal muscular atrophy.

Adult SMA REACH: A UK clinical network and real-world data collection study for adults living with spinal muscular atrophy.

Journal: Journal of neuromuscular diseases

Published: March 14, 2026

Showing 1-12 of 1,076

Last Updated: 06/30/2026